The Rome III Classification of Dyspepsia: Will It Help Research?

Talley, Nicholas J.; Ruff, Kevin C.; Jiang, Xuan; Jung, Hye Kyung

doi:10.1159/000121347

Cited by 26 publications

(26 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The term "dyspepsia" has been confusing in the past. Patients do not use the term and physicians have variable interpretations, minimizing its usefulness (7,14). The difficulty in differentiating between dyspepsia and GERD symptoms was also reported; a recent paper revealed an over-diagnosis of GERD and under-diagnosis of functional dyspepsia in a US community.…”

Section: Turk J Gastroenterol 2016; 27: 73-80mentioning

confidence: 99%

The role of diet in the overlap between gastroesophageal reflux disease and functional dyspepsia

Chirilă¹,

Morariu²,

Bărboi³

et al. 2016

Turk J Gastroenterol

View full text Add to dashboard Cite

Section: Turk J Gastroenterol 2016; 27: 73-80mentioning

confidence: 99%

The role of diet in the overlap between gastroesophageal reflux disease and functional dyspepsia

Chirilă¹,

Morariu²,

Bărboi³

et al. 2016

Turk J Gastroenterol

View full text Add to dashboard Cite

“…Therefore, some degree of overlap between GERD and FGIDs would appear inevitable, by chance alone due to the given high prevalence rate. Indeed recent data show that patients with GERD suffer more commonly from FGIDs 7-9…”

Section: Introductionmentioning

confidence: 99%

Overlap of Erosive and Non-erosive Reflux Diseases With Functional Gastrointestinal Disorders According to Rome III Criteria

Noh¹,

Jung²,

Kim³

et al. 2010

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Background/AimsGastroesophageal reflux disease (GERD) is increasing in Asian countries. Functional dyspepsia (FD) or irritable bowel syndrome (IBS) are also prevalent and commonly overlapped with GERD. This study was conducted to compare the proportion and risk factors for overlapping reflux esophagitis (RE) and non-erosive reflux disease (NERD) with functional gastrointestinal disorders (FGIDs).MethodsA total of 2,388 [male, 55.9%; mean age (± SD), 43.2 years (± 8.4)] Korean subjects who underwent the upper endoscopy for health screening were prospectively included. The subjects were asked about demographic, medical and social history by using a structured questionnaire, and FD and IBS were assessed according to the Rome III criteria.ResultsThe subjects with RE were 286 (12.0%, male 88.5%, 42.8 years) and 74 subjects had NERD (3.1%) while the prevalence of FD and IBS were 8.1% and 10.1%, respectively. The proportion of FD and IBS in NERD was higher than that of RE (74.3% vs. 10.5%, p = 0.000; 41.9% vs. 11.2%, p = 0.000, respectively). The epigastric pain syndrome (EPS) was more prevalent than postprandial distress syndrome in NERD. According to multiple regression analysis, high somatization score and the presence of FD increased the odd ratio for NERD. However, male gender and current smoker were significant risk factors for RE.ConclusionsCompared to RE, NERD is more frequently overlapped with FD, especially EPS, and also are associated with significantly increased frequency of IBS. Our data draws attention to the possibility of subgrouping FGIDs and GERD to be important in understanding the pathophysiology of these conditions.

show abstract

“…A number of treatment strategies have been evaluated for FD, with acid-suppressive therapy being potentially effective for EPS and prokinetics for PDS [10]. However, the level of evidence for the efficacy of these approaches is low, and in particular there is a lack of prokinetic drugs of proven value for this condition.…”

Section: Drug Profilementioning

confidence: 99%

Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome

Altan¹,

Masaoka²,

Farré³

et al. 2012

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Functional dyspepsia (FD) is a highly prevalent condition with major socioeconomic and healthcare impact. To date, no pharmacological treatment for FD has been approved. The Rome consensus proposed to subdivide FD into postprandial distress syndrome (PDS), characterized by meal-related symptoms and epigastric pain syndrome, characterized by pain and burning. Acotiamide (Z-338 or YM443) is a new drug, developed for the treatment of FD. Acotiamide enhances acetylcholine release from enteric neurons through muscarinic receptor antagonism and acetycholinesterase inhibition, thereby enhancing gastric emptying and gastric accommodation. Acotiamide was evaluated in FD in clinical studies in Europe, Japan and the USA, beneficial effects were observed for the PDS symptoms of postprandial fullness and early satiation, with a dose of 100 mg three-times a day. A 4-week placebo-controlled Phase III study in PDS patients in Japan confirmed efficacy of acotiamide in relieving postprandial fullness, early satiation and upper abdominal bloating.

show abstract

The Rome III Classification of Dyspepsia: Will It Help Research?

Cited by 26 publications

References 80 publications

The role of diet in the overlap between gastroesophageal reflux disease and functional dyspepsia

The role of diet in the overlap between gastroesophageal reflux disease and functional dyspepsia

Overlap of Erosive and Non-erosive Reflux Diseases With Functional Gastrointestinal Disorders According to Rome III Criteria

Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome

Contact Info

Product

Resources

About